Bank of Nova Scotia Has $68.82 Million Stock Holdings in CVS Health Corporation $CVS

Bank of Nova Scotia lifted its holdings in CVS Health Corporation (NYSE:CVS) by 237.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 912,809 shares of the pharmacy operator’s stock after buying an additional 642,628 shares during the quarter. Bank of Nova Scotia owned about 0.07% of CVS Health worth $68,817,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. raised its stake in shares of CVS Health by 72.1% in the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 142 shares during the last quarter. Corundum Trust Company INC bought a new stake in shares of CVS Health during the third quarter valued at approximately $29,000. Front Row Advisors LLC increased its holdings in shares of CVS Health by 436.5% in the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 371 shares in the last quarter. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of CVS Health in the second quarter valued at approximately $36,000. Finally, SOA Wealth Advisors LLC. raised its position in CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 131 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on CVS shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of CVS Health in a research report on Thursday, December 4th. Morgan Stanley boosted their target price on CVS Health from $89.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Piper Sandler reiterated an “overweight” rating and issued a $101.00 price target (up from $99.00) on shares of CVS Health in a report on Wednesday, December 10th. Argus lowered their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Finally, Bank of America dropped their price objective on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a report on Tuesday, January 27th. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.05.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Stock Performance

CVS stock opened at $76.14 on Monday. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The company has a market cap of $96.87 billion, a P/E ratio of 55.17, a price-to-earnings-growth ratio of 0.79 and a beta of 0.49. The business’s fifty day moving average is $78.17 and its 200-day moving average is $77.83.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. During the same period in the previous year, the firm earned $1.19 earnings per share. The firm’s quarterly revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. CVS Health’s dividend payout ratio is 192.75%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.